Graphene oxide (GO) has mainly been studied as a carrier for intracellular delivery of therapeutics. Prior observations indicated a cell type–dependent interaction pattern: GO tended to remain associated with the plasma membrane of cancer cells while being internalised by non-cancerous epithelial cells. This study tested whether membrane-associated GO can act as a nano-bio platform to present bioactive ligands at the cell surface and thereby influence receptor-mediated signalling, focusing on integrin receptors in glioblastoma models.
The investigators non-covalently complexed an RGD-containing peptide with GO to target integrin receptors at the plasma membrane. Peptide association with GO was quantified using a 2,4,6-trinitrobenzene sulfonic acid (TNBSA) assay. GO and GO:RGD were characterised by atomic force microscopy (AFM), X-ray photoelectron spectroscopy (XPS), X-ray diffraction (XRD), and colloidal measurements. Cellular interaction, uptake, motility, and focal adhesion signalling readouts were assessed in cell culture models.
Immediately after complexation, approximately 70% of RGD was associated with GO as measured by TNBSA. Physicochemical characterisation found that peptide association increased the nitrogen signal in XPS and shifted the principal GO XRD peak, while nanosheet morphology was retained on AFM. Colloidal properties were measured, but specific numerical values for size distribution, zeta potential, and other colloidal metrics were not reported in the source summary.
Biological experiments used two glioblastoma cell lines, U87 and U251, selected for differing integrin-positive fractions, and a non-cancerous bronchial epithelial cell line, BEAS-2B. Confocal microscopy indicated that both GO and GO:RGD remained predominantly localised on the plasma membrane in U87 and U251 cells. In contrast, BEAS-2B cells showed greater intracellular localisation of the material. The source did not provide detailed quantitation of integrin expression levels or the exact percentages of membrane-associated versus internalised material beyond these qualitative differences.
Functional motility assays showed that treatment with GO:RGD significantly reduced key indicators of cell motility in U87 and U251 glioblastoma cells. Specifically, cell velocity decreased, and trajectory and mean-square-displacement analyses supported restricted cellular movement following GO:RGD treatment. By contrast, free RGD peptide alone did not produce a significant effect on motility. GO alone caused a smaller reduction in motility, but this effect was observed only in U251 cells. No treatment—GO, RGD, or GO:RGD—significantly altered the motility of BEAS-2B epithelial cells.
Flow cytometry analysis showed a reduced pFAK-associated signal in GO:RGD-treated U87 cells, indicating an effect on focal adhesion kinase phosphorylation that is consistent with altered integrin-linked signalling. The source reports this reduced pFAK-associated signal but does not provide specific fold-change numbers or the complete panel of phosphorylated proteins examined.
These data establish a proof of concept that the cell-line-dependent plasma membrane localisation of GO can be exploited as a membrane-associated platform to present cell-surface-active ligands such as RGD, modulate integrin-mediated signalling, and influence cell behaviour. In glioblastoma models tested here, membrane-associated GO:RGD restricted cell motility and reduced a pFAK-associated signal, effects not reproduced by free peptide and only partially by GO alone in one cell line. The findings support the potential development of GO-based platforms intended to modulate receptor-mediated signalling at the cell surface rather than delivering cargo intracellularly.
The summary reports key qualitative and some quantitative outcomes but omits several experimental specifics. The source did not include detailed numerical values for: complete colloidal characterisation metrics (size distributions, zeta potentials), quantitative integrin expression levels for each cell line, exact percentages of membrane vs intracellular localisation by cell type, full statistical values (e.g., p values, effect sizes), or fold changes for pFAK signal. Toxicity, long-term effects, and in vivo validation were not reported in the provided summary. These details were not reported in the source material presented here.
The study demonstrates that GO associated with the plasma membrane can present an RGD ligand to modulate integrin-related signalling and cell motility in glioblastoma cell lines. The approach offers a membrane-focused nano-bio interface distinct from intracellular delivery and supports further exploration of GO-based platforms for modulating receptor-mediated cellular responses. The authors declared no competing interests and acknowledged funding from the Engineering and Physical Sciences Research Council and Agencia Estatal de Investigación.